Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking. OBJECTIVE: To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The Randomized European Celecoxib Trial (REACT) was a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing 2 years of adjuvant celecoxib vs placebo among 2639 patients recruited between January 19, 2007, and November 1, 2012, with follow-up 10 years after treatment completion. Eligible patients had completely resected breast cancer with local and systemic therapy according to local practice. Patients with ERBB2-positive or node-negative and T1, grade 1 tumors were not eligible. Randomization was in a 2:1 ratio between celecoxib or placebo. Statistical analysis was performed from May 5, 2019, to March 5, 2020. INTERVENTIONS: Patients received celecoxib, 400 mg, or placebo once daily for 2 years. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival (DFS), analyzed in the intention-to-treat population using Cox proportional hazards regression and log-rank analysis. Follow-up is complete. RESULTS: A total of 2639 patients (median age, 55.2 years [range, 26.8-86.0 years]) were recruited; 1763 received celecoxib, and 876 received placebo. Most patients' tumors (1930 [73%]) were estrogen receptor positive or progesterone receptor positive and ERBB2 negative. A total of 1265 patients (48%) had node-positive disease, and 1111 (42%) had grade 3 tumors. At a median follow-up of 74.3 months (interquartile range, 61.4-93.6 years), DFS events had been reported for 487 patients (19%): 18% for those who received celecoxib (n = 323; 5-year DFS rate = 84%) vs 19% for those who received placebo (n = 164; 5-year DFS rate = 83%); the unadjusted hazard ratio was 0.97 (95% CI, 0.80-1.17; log-rank P = .75). Rates of toxic effects were low across both treatment groups, with no evidence of a difference. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, patients showed no evidence of a DFS benefit for 2 years' treatment with celecoxib compared with placebo as adjuvant treatment of ERBB2-negative breast cancer. Longer-term treatment or use of a higher dose of celecoxib may lead to a DFS benefit, but further studies would be required to test this possibility. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02429427 and isrctn.org Identifier: ISRCTN48254013.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.04.014 · Cited by 1,097
Cited by
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Benjamin, D. J., Haslam, A., & Prasad, V. (2024) · Cancer Medicine · doi:10.1002/cam4.7049 · Cited by 30
Konara Mudiyanselage, S. P., Wu, Y.-L., Kukreti, S., Chen, C.-C., Lin, C.-N., Tsai, Y.-T., Ku, H.-C., Fang, S.-Y., Wang, J.-D., & Ko, N.-Y. (2023) · Breast Cancer · doi:10.1007/s12282-022-01413-6 · Cited by 22
Metadata
- Authors
- Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., Hicks, J., Makris, A., Evans, A., Loibl, S., Denkert, C., Murray, E., Grieve, R., Coleman, R., Borley, A., Schmidt, M., Rautenberg, B., Kunze, C. A., Rhein, U., Mehta, K., Mousa, K., Dibble, T., Lu, X. L., von Minckwitz, G., Bliss, J. M., Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators, Tierbach, V., Bogle, R., Badman, P., Churn, M., Newby, J., Stickeler, E., Tranter, H., Nichol, S., Winter, M. C., Barthelmes, L., Wardley, A., Chakrabarti, A., Barthakur, U., Hrouda, D., Riddle, P. J., Stewart, A., Intrivici, C., Walji, N., Pettit, L., Lupton, S., Woodings, P., Chandrasekharan, S., Maxwell, W., Simmonds, A., Mehra, R., Tsalic, M., Anand, G., Allerton, R., Shah, K., Hadjiminas, D., Maher, J., Dhadda, A., Bhatt, L., Venkitaraman, R., Vinayan, A., Taylor, A., Hatton, M., Jones, E., McAdam, K., Harding-MacKean, C., Harries, M., Silva, S., Persic, M., Vaidya, J., Rigg, A., Wyld, L., Hamed, H., Shujja-Ud-Din, O. S., Webster, R., Wheatley, D., Jafri, M., Al-hasso, A., Rehman, S., Waters, S. H., Fraser, J., Hayward, R. L., Abraham, J. M., Passant, H., Wai-Ling King, J., Pope, V., Skene, A. I., Scott, L. C., Maclennan, M. K., Rea, D. W., Levitt, N. C., Khan, S., Hönig, A., Müller, B., Deutsch, G., Hanusch, C., Harbeck, N., Lemster, S., Klein, T., Reimer, T., Meerpohl, H.-G., Winzer, K.-J., Süttmann, G., Jackisch, C., Sallmann, A., Klemm, W., Schrader, I., Kamer, D., Schem, C., Liedtke, C., Fuchs, R., Thomssen, C., Terhaag, J., Hitschold, T., Wolf, H., Carstensen, M., Brückner, B., Richter, P., Gerber, B., Burkamp, U., Graßhoff, S.-T., Simon, E., Zahm, D.-M., von der Assen, A., Zahm, D. M., Graffunder, G., Bartzke, G., Sommer, H., Neunhöffer, T., Conrad, B., Schulmeyer, E., Hofmann, M., Breitbach, P. G., Scharl, A., Papez-Rodosek, L., Bender, A., Durmus, G., Klare, P., Deuker, J.-U., Knörzer, T., Solomayer, E. F., Bischoff, J., Stefek, A., Prell, W., Weiss, E., Steffens, C.-C., Ober, A., Emons, G., Tesch, H., Beckmann, M., Bauer, W., Hackmann, J., Bechler, J., Langanke, D., Weise, W., Pelzl, A., Ringel, R., Schwarz, M., Latos, K., Lampe, D., Siebers, J.-W., Heinrich, B., Kleine-Tebbe, A., Schumacher, C., Uleer, C., Kirste, T., Heyl, V., Müller, S., Katz, C., Müller, L., Krabisch, P., Palatty, J., Höffkes, H.-G., Behrens, O., Faust, E., Gnauert, K., Strittmatter, H.-J., Graf, H., Baake, G., Gatzweiler, A., Sprengnetter, D., Rezai, M., Ufermann, W., Lindner, C., Rossmann, A., Kunz, T., Noesselt, T., Dewitz, T. H., Dietrich, M., Lerchenmüller, C., Wagner, H., Parisis, V., Mattner, U., Klutinus, N., Bechtner, C., Dall, P., Scholz, H., Rösel, S. B., Bettscheider, J., Krauss, K., Sawitzki, K., Vehling-Kaiser, U., Olbermann, A., Baerens, D.-T., Balwanz, A.-E., Schieder, H., Peters, N., Hahn, L., Ladda, E., Demandt, M., Ackermann, S., Kolberg, H.-C., Seifert, B., Berger, R., Kraudelt, S., Decker, T., Hänle, C., Nacke, A., Stauder, H., Fricke, H.-C., Kipp, B., Stauter, F., Ossenbühl, D. P., Marx, M., Hanf, V., Schwoerer, M., Dallacker, W., Hesse, T., Denschlag, D., Nestle-Krämling, C., Buck, I., Romann, D., Dohnicht, S., & Hornbacher, B.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-09-01
- Volume
- 7
- Issue
- 9
- Pages
- 1291
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3182080602
- Cited by
- 50
- References
- 2
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2021.2193
- The paper
- Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., Hicks, J., Makris, A., Evans, A., Loibl, S., Denkert, C., Murray, E., Grieve, R., Coleman, R., Borley, A., Schmidt, M., Rautenberg, B., Kunze, C. A., Rhein, U., . . . Hornbacher, B. (2021). Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.2193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.